Published in Cancers (Basel) on March 12, 2010
Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med (1995) 26.60
RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev (2001) 26.16
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med (2001) 24.51
The biology of vascular endothelial growth factor. Endocr Rev (1997) 13.70
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med (2006) 13.54
The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res (1969) 13.27
Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg (1970) 12.72
Growing roles for the mTOR pathway. Curr Opin Cell Biol (2005) 11.66
Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med (1998) 11.03
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A (2003) 10.71
Melanoma biology and new targeted therapy. Nature (2007) 10.71
Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol (2001) 10.20
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol (2005) 9.72
Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol (2001) 9.68
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol (1996) 9.68
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood (2009) 9.24
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med (2006) 8.26
Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst (1994) 7.20
Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol (2007) 6.68
Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA (1994) 6.36
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest (2006) 5.62
The emerging role of CTLA-4 as an immune attenuator. Immunity (1997) 5.35
Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst (1989) 5.28
High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol (2001) 4.84
Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg (1995) 4.37
Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev (2006) 4.24
High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am (2000) 4.19
High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res (2004) 3.94
Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. J Clin Oncol (2008) 3.82
A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). J Clin Oncol (1983) 3.80
Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol (2005) 3.73
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol (2008) 3.58
Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. J Clin Oncol (2002) 3.05
KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol (2000) 2.99
The biology of cancer invasion and metastasis. Adv Cancer Res (1978) 2.94
Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol (2003) 2.87
How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes memorial Award lecture. Cancer Res (1986) 2.69
Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: possible involvement of TNFalpha and IL-1alpha. Int J Cancer (2000) 2.64
Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol (2002) 2.57
Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. Proc Natl Acad Sci U S A (2009) 2.56
Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma. J Clin Oncol (2008) 2.53
Prognostic significance of hypopigmentation in malignant melanoma. Arch Dermatol (1987) 2.51
Increased expression of stem cell markers in malignant melanoma. Mod Pathol (2006) 2.39
Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J Clin Oncol (2000) 2.37
Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine (2000) 2.25
Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst (1998) 2.17
Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol (1994) 2.10
Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. J Clin Oncol (2003) 1.74
Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity. Adv Drug Deliv Rev (2007) 1.66
Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor. J Clin Oncol (2008) 1.61
Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine. Clin Cancer Res (2001) 1.59
Copper binding by tetrathiomolybdate attenuates angiogenesis and tumor cell proliferation through the inhibition of superoxide dismutase 1. Clin Cancer Res (2006) 1.58
Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Int J Cancer (2005) 1.55
The biologic forms of malignant melanoma. Hum Pathol (1986) 1.51
Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg (1992) 1.50
Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment. Br J Dermatol (2007) 1.49
Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J Clin Oncol (2005) 1.48
Angiogenesis inhibition: a review. Pharmacol Ther (1994) 1.40
Histological regression in primary cutaneous melanoma: recognition, prevalence and significance. Histopathology (1992) 1.39
Melanoma stem cells: the dark seed of melanoma. J Clin Oncol (2008) 1.37
Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients. J Clin Oncol (2003) 1.34
Malignant melanoma of the skin. I. The association of tumor depth and type, and patient sex, age, and site with survival. Cancer (1983) 1.32
Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res (1996) 1.31
Spontaneous regression of human melanoma: clinical and experimental studies. Cancer (1960) 1.30
Lipid composition of human malignant melanoma tumors at various levels of malignant growth. Eur J Biochem (1979) 1.21
Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. Clin Cancer Res (1999) 1.20
Phase II study of extended-dose temozolomide in patients with melanoma. J Clin Oncol (2008) 1.19
Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses. J Clin Oncol (2003) 1.17
Gangliosides of human melanoma. J Natl Cancer Inst (1987) 1.17
Thin malignant melanomas with regression and metastases. Arch Dermatol (1987) 1.16
In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity. J Immunol (1998) 1.13
Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. Clin Cancer Res (2003) 1.12
Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes. Ann Surg (2002) 1.11
Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial. J Clin Oncol (2002) 1.10
A clinicopathologic study of prognostic factors in cutaneous malignant melanoma. Surg Gynecol Obstet (1977) 1.09
GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res (1995) 1.09
Expression of Bcl-2 family members in human melanocytes, in melanoma metastases and in melanoma cell lines. Melanoma Res (1998) 1.04
Role of an anti-epidermal growth factor receptor in treating cancer. Cancer Metastasis Rev (1999) 1.02
Regression in malignant melanoma. A histologic feature without independent prognostic significance. Cancer (1985) 1.01
Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J Am Coll Surg (1998) 1.00
Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. J Clin Oncol (1997) 0.96
T-cell recognition of melanoma-associated antigens. J Cell Physiol (2000) 0.96
Vaccine therapy for malignant melanoma. CA Cancer J Clin (1996) 0.93
Infiltration of primary and metastatic melanomas with macrophages of the 25F9-positive phenotype. Cancer Immunol Immunother (1987) 0.91
Vaccine-induced CD8+ T-cell responses to MAGE-3 correlate with clinical outcome in patients with melanoma. Clin Cancer Res (2003) 0.90
Inhibiting the growth of malignant melanoma by blocking the expression of vascular endothelial growth factor using an RNA interference approach. Br J Dermatol (2005) 0.90
DTIC and combination therapy for melanoma: III. DTIC (NSC 45388) Surgical Adjuvant Study COG PROTOCOL 7040. Cancer (1981) 0.88
A phase I trial of SD-9427 (progenipoietin) with a multipeptide vaccine for resected metastatic melanoma. Clin Cancer Res (2003) 0.88
Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response. Cancer Res (1994) 0.88
Evidence that treatment with vaccinia melanoma cell lysates (VMCL) may improve survival of patients with stage II melanoma. Treatment of stage II melanoma with viral lysates. Cancer Immunol Immunother (1987) 0.87
Sequential administration of GM-CSF (Sargramostim) and IL-2 +/- autologous vaccine as adjuvant therapy in cutaneous melanoma: an interim report of a phase II clinical trial. Cancer Biother Radiopharm (2008) 0.86
The importance of anatomic site in prognosis in patients with cutaneous melanoma. Arch Surg (1991) 0.83
Regression in thin malignant melanoma. Microscopic diagnosis and prognostic importance. Arch Dermatol (1985) 0.82
Human dendritic cells genetically engineered to express a melanoma polyepitope DNA vaccine induce multiple cytotoxic T-cell responses. Clin Cancer Res (2001) 0.82
A phase III randomized, double-blind multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma. Cancer (1995) 0.82
Adjuvant immunotherapy in melanoma with irradiated autologous tumor cells and low dose cyclophosphamide. J Surg Oncol (1997) 0.80
Why do melanomas ulcerate? J Cutan Pathol (1984) 0.77
Thin (less than or equal to 1 mm) melanomas of the extremities are biologically favorable lesions not influenced by regression. Ann Surg (1985) 0.77
Perioperative adjuvant biotherapy in high-risk resected cutaneous melanoma: the results of 5 years of follow-up. Melanoma Res (2007) 0.76
Keynote address: perspectives on the use of interleukin-2 in cancer treatment. Cancer J Sci Am (1997) 0.76
CD34+ cells in the peripheral blood transport herpes simplex virus DNA fragments to the skin of patients with erythema multiforme (HAEM). J Invest Dermatol (2005) 1.60
Wnt5A activates the calpain-mediated cleavage of filamin A. J Invest Dermatol (2009) 1.32
SOX10 ablation arrests cell cycle, induces senescence, and suppresses melanomagenesis. Cancer Res (2013) 0.90
Stress up-regulates neuronal expression of the herpes simplex virus type 2 large subunit of ribonucleotide reductase (R1; ICP10) by activating activator protein 1. J Neurovirol (2005) 0.89
Cytokines and growth factors expressed by human cutaneous melanoma. Cancers (Basel) (2010) 0.89
Sequential administration of GM-CSF (Sargramostim) and IL-2 +/- autologous vaccine as adjuvant therapy in cutaneous melanoma: an interim report of a phase II clinical trial. Cancer Biother Radiopharm (2008) 0.86